Global Neurosyphilis Market Size, Share, Forecast Report, 2020-2027

Neurosyphilis is the infection of spinal cord and brain. It is most common in an individual who have untreated syphilis for long period of time. This is mainly caused due to bacteria called Treponema pallidum. This is the bacteria which causes syphilis. After getting infected with syphilis for the first time, there are chances of neurosyphilis after 10-20 years later. The major symptoms of neurosyphilis are blindness, abnormal walk, confusion, depression, dementia, headache, irritability, incontinence, poor concentration, numbness in the toes, feet, or legs, seizures, tremors, stiff neck, visual disturbances, and weakness. There are possibility of no symptoms of neurosyphilis. Out of all types of neurosyphilis, asymptomatic neurosyphilis is the most common type.

Considering the market scenario of global neurosyphilis, increasing funding for research, clinical trials, and new product development are driving the growth for the market. Government and companies are investing large amount of money to derive effective cure for neurosyphilis. Adoption of technologically advanced diagnostic medical devices are another important driver for the market. Some other factors like increasing awareness, rising demand from emerging markets, government support to improve public healthcare, and changing healthcare practices are also major factors for the market growth.

The global neurosyphilis market is growing steadily and is expected to continue its growth during the forecast period. Global neurosyphilis market is expected to grow at the CAGR of ~3.9% during the forecast period and is estimated to reach USD 957.4 million by 2023.
Key players for global neurosyphilis market:

Some of the key players in this market are: Abbott (US), Bayer AG (Germany), Eli Lilly and Company (US), GlaxoSmithKline plc. (UK), Novartis AG (Switzerland), Pfizer Inc. (US), Sanofi (France), and others.

Segments:

Global neurosyphilis market has been segmented on the basis of type which comprise asymptomatic neurosyphilis, meningeal neurosyphilis, meningovascular neurosyphilis, general paresis, tabes dorsalis, and others.

On the basis of diagnosis, the market is segmented into physical exam, blood test, spinal tap, imaging tests, and others. Blood test is further subsegmented into Venereal disease research laboratory (VDRL) test, Fluorescent treponemal antibody absorption (FTA-ABS), Rapid plasma reagin (RPR), Treponema pallidum particle agglutination assay (TPPA), and others. Imaging tests is further sub-segmented into Computed Tomography (CT), X-rays, Magnetic resonance imaging (MRI), and others.

On the basis of treatments, the market has been segmented into antibiotic penicillin, antibiotics probenecid, ceftriaxone and others. Antibiotic penicillin is further sub-segmented into Injection and oral.

On the basis of end user, it is segmented into hospital and clinics, medical research centers, academic institutes, and others.